TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15449756

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 0
Study: 12699795

Group type: EXPERIMENTAL
Intervention: Cavaterm thermal balloon endometrial ablation system
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nd:YAG laser
Number of subjects: 72
Study: 10543808

Group type: EXPERIMENTAL
Intervention: L. rhamnosus 19070‐2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 12246
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L. rhamnosus LGG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L. delbrueckii subsp. lactis CHCC 2329
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L. casei subsp. alactus CHCC 3137
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All selected strains
Number of subjects: 12
Study: 7773098

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 88
Study: 2197852

Group type: COMPARATOR
Intervention: Aspartame alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspartame plus sucrose (3.51 mmol sucrose/kg body wt)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspartame plus sucrose
Number of subjects: 12
Study: 376029

Group type: EXPERIMENTAL
Intervention: Shoulder movement restricted for the first 7 days after operation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Early arm exercises encouraged
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Shoulder immobilization
Number of subjects: 64
Study: 30587520

Group type: EXPERIMENTAL
Intervention: Ventro-oral thalamotomy
Number of subjects: 171
Study: 28126231

Group type: EXPERIMENTAL
Intervention: MedDiet+EVOO
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: MedDiet+Nuts
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group (low-fat diet)
Number of subjects: 276
Study: 26547518

Group type: EXPERIMENTAL
Intervention: Multicomponent, nonpharmacologic interventions (MNI)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (Group U)
Number of subjects: 160
Study: 24861134

Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg loading dose on Day 1 followed by 10 mg once daily for 8 days with a single 25 mg dose of warfarin on Day 4
Number of subjects: 14

Group type: COMPARATOR
Intervention: Single dose of warfarin on Day 1
Number of subjects: 14
Study: 22119181

Group type: EXPERIMENTAL
Intervention: Mindful awareness in body-oriented therapy (MABT)
Number of subjects: 46
Study: 19157816

Group type: EXPERIMENTAL
Intervention: High-viscosity NVP preload (700 poise)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Medium-viscosity GLM preload (410 poise)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-viscosity CE preload (10 poise)
Number of subjects: 31
Study: 18240627

Group type: EXPERIMENTAL
Intervention: Education-Counselling Interview (ECI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall study sample
Number of subjects: 200
Study: 16234230

Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) supplementation
Number of subjects: 72
Study: 11988598

Group type: EXPERIMENTAL
Intervention: Stroke patients (n=5)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal controls (n=16)
Number of subjects: 21
Study: 9816765

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 10158113

Group type: EXPERIMENTAL
Intervention: Intracoronary diltiazem (ICD) 2.5 mg before lasing
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intracoronary diltiazem (ICD) 2.5 mg before and after lasing
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no ICD)
Number of subjects: 150
Study: 30375485

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) applied across the primary motor cortex
Number of subjects: 170000
Study: 25853736

Group type: EXPERIMENTAL
Intervention: RNAzol
Number of subjects: 0

Group type: COMPARATOR
Intervention: RNAzol modified protocol
Number of subjects: 0
Study: 24535407

Group type: EXPERIMENTAL
Intervention: Longitudinal whole-body magnetic resonance imaging (wb-MRI)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Radiological stable disease (MRI-SD)
Number of subjects: 63
Study: 23370087

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 66
Study: 20626052

Group type: EXPERIMENTAL
Intervention: Chinese herbal point-patch
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 43
Study: 18311852

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Established treatment
Number of subjects: 0
Study: 17198588

Group type: EXPERIMENTAL
Intervention: Standardized Tertiary Rehabilitation (STR) including physical therapy and occupational therapy (OT)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Routine intervention of internal medicine (Control)
Number of subjects: 1209
Study: 12556783

Group type: EXPERIMENTAL
Intervention: Blended current (Group B)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Pure cutting current (Group A)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Pure cutting followed by blended current (Group C)
Number of subjects: 186
Study: 11168329

Group type: EXPERIMENTAL
Intervention: Intensified Conventional Treatment (ICT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 88
Study: 9184780

Group type: EXPERIMENTAL
Intervention: Intervention to increase mammography screening
Number of subjects: 1144
Study: 1289367

Group type: EXPERIMENTAL
Intervention: Piroximone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: No inotropic support (Control)
Number of subjects: 80
Study: 4089188

Group type: EXPERIMENTAL
Intervention: Sulpiride 2.5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sulpiride 5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sulpiride 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sulpiride 20 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Arginine HCl infusion (0.33G/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29483559

Group type: EXPERIMENTAL
Intervention: Tailored mobile coaching (TMC)
Number of subjects: 148
Study: 25068802

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: SHAM intervention (control)
Number of subjects: 17
Study: 24074713

Group type: EXPERIMENTAL
Intervention: High-dose aspartate-ornithine granules (6 g bid po)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low-dose aspartate-ornithine granules (3 g bid po)
Number of subjects: 72
Study: 21437745

Group type: EXPERIMENTAL
Intervention: Usual oral information plus an information leaflet about SSI (group O/L)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Usual oral information alone (group O)
Number of subjects: 207
Study: 18534421

Group type: EXPERIMENTAL
Intervention: Portable, continuous enhanced circulation therapy (CECT) + low-molecular-weight heparin (LMWH)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 277
Study: 16964698

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 50
Study: 12803263

Group type: EXPERIMENTAL
Intervention: Propofol (1 mg kg(‐1) followed by 10 mg kg(‐1) h(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil (0.5 microg kg(‐1) followed by 0.2 microg kg(‐1) min(‐1))
Number of subjects: 40
Study: 12119640

Group type: EXPERIMENTAL
Intervention: Greater initial weight loss induced without changes in lifestyle (e.g. liquid formula diets or anorectic drugs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-2 years integrated weight maintenance programme consisting of lifestyle interventions (dietary change, nutritional education, behaviour therapy, increased physical activity)
Number of subjects: 0
Study: 8682976

Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg/day) + sleep deprivation (6 treatments at 4-5 day intervals)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Amitriptyline (150 mg/day)
Number of subjects: 51
Study: 1514724

Group type: EXPERIMENTAL
Intervention: 60 mg ketorolac
Number of subjects: 47

Group type: COMPARATOR
Intervention: 100 mg meperidine and 50 mg hydroxyzine
Number of subjects: 47
Study: 6487909

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 20
Study: 29575909

Group type: EXPERIMENTAL
Intervention: NRTIs with predicted reduced activity (GSS <1)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: NRTIs with intermediate activity (GSS = 1)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: NRTIs with high activity (GSS >1)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Second-line therapy with darunavir/ritonavir or lopinavir/ritonavir
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Suboptimal adherence, high predicted RTI activity, or low NRTI mutations
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: RTIs with predicted reduced activity
Number of subjects: 387
Study: 26671485

Group type: EXPERIMENTAL
Intervention: Lidocaine 1 % infiltration at port sites before incision (preincisional)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Lidocaine 1 % infiltration at port sites after trocar removal (preclosure)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Saline infiltration at port sites before incision (preincisional control)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Saline infiltration at port sites after trocar removal (preclosure control)
Number of subjects: 226
Study: 25341682

Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (regular medical treatment)
Number of subjects: 32
Study: 24135530

Group type: EXPERIMENTAL
Intervention: MCI-186 (edaravone) with a loading dose of 0.08 mg/kg + 0.2 mg/kg/h infusion
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MCI-186 (edaravone) with a loading dose of 0.16 mg/kg + 0.4 mg/kg/h infusion
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 20954761

Group type: EXPERIMENTAL
Intervention: Strong African American Families program
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 337
Study: 18239552

Group type: EXPERIMENTAL
Intervention: High saturated:unsaturated fat (SFA:USFA) diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lower SFA:USFA diet
Number of subjects: 18
Study: 16980316

Group type: EXPERIMENTAL
Intervention: Acupuncture (10 individualised treatments)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 241
Study: 15295414

Group type: EXPERIMENTAL
Intervention: Moderate atherosclerosis (CAC score of 100-400 Agatston units)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Severe atherosclerosis (CAC score > or =400 Agatston units)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Increasing severity of atherosclerosis
Number of subjects: 220
Study: 11518437

Group type: EXPERIMENTAL
Intervention: Physical exercise programme (regular group exercises and home exercises for a period of three months)
Number of subjects: 47
Study: 9253568

Group type: EXPERIMENTAL
Intervention: Monoethylglycinexylidide synthesis
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Factor V index (FVI)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prothrombin time index (PTI)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Plasma bilirubin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase (ASAT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase (ALAT)
Number of subjects: 71
Study: 8433884

Group type: EXPERIMENTAL
Intervention: Glucose with amino acids (1.5 g.kg‐1.d‐1) i.v.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 23
Study: 3127815

Group type: EXPERIMENTAL
Intervention: doxycycline 0.1 g x 2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: demethylchlortetracycline (DMCT) 0.3 g x 2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: lymecycline 0.6 g x 2
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 31166214

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 12

Group type: COMPARATOR
Intervention: Steroids and other immunosuppressants (concurrently treated)
Number of subjects: 12
Study: 29979644

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 27716283

Group type: EXPERIMENTAL
Intervention: U-500R TID (n=162)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: U-500R BID (n=163)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 325
Study: 25091192

Group type: EXPERIMENTAL
Intervention: Molecular resonance (MR)
Number of subjects: 873

Group type: COMPARATOR
Intervention: Cold-knife (CK)
Number of subjects: 873

Group type: COMPARATOR
Intervention: Monopolar cautery (MPC)
Number of subjects: 873
Study: 22303845

Group type: EXPERIMENTAL
Intervention: Predator urine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-predator urine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Defensive behaviors (vigilance and fleeing)
Number of subjects: 56
Study: 20303833

Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both VCV and PCV
Number of subjects: 60
Study: 18394765

Group type: EXPERIMENTAL
Intervention: MV and LJEV together at 9 months (Group 2)
Number of subjects: 571

Group type: COMPARATOR
Intervention: MV and LJEV at 9 and 10 months, respectively (Group 3)
Number of subjects: 571

Group type: COMPARATOR
Intervention: LJEV administered at age of 8 months and MV at 9 months (Group 1)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: All groups (Group 1, Group 2, Group 3)
Number of subjects: 571
Study: 15933423

Group type: EXPERIMENTAL
Intervention: edrecolomab (900 mg total)
Number of subjects: 377

Group type: COMPARATOR
Intervention: observation
Number of subjects: 377
Study: 12908073

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10571605

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg once daily
Number of subjects: 396

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 396
Study: 8561641

Group type: EXPERIMENTAL
Intervention: CP-treated group (St. Thomas' Hospital cardioplegic solution No. 1 plus CP 10 mmol/L)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (St. Thomas' Hospital cardioplegic solution No. 1)
Number of subjects: 50
Study: 1871547

Group type: EXPERIMENTAL
Intervention: Bedtime UDCA 7 mg/kg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mealtime UDCA 10 mg/kg/day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Bedtime UDCA (average minimum effective dose) 8.4 mg/kg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Repeated-release tablet formulation of UDCA
Number of subjects: 44
Study: 6221200

Group type: EXPERIMENTAL
Intervention: THIP (4,5,6,7‐tetrahydroisoxazolo‐[5,4,‐c] pyridin‐3‐ol) administered orally for 2 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: THIP (4,5,6,7‐tetrahydroisoxazolo‐[5,4,‐c] pyridin‐3‐ol) at maximum levels
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-dose THIP therapy
Number of subjects: 5
Study: 30059193

Group type: COMPARATOR
Intervention: AAA tablet
Number of subjects: 45

Group type: COMPARATOR
Intervention: NXA tablet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both tablet formulations
Number of subjects: 45
Study: 30558053

Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 53
Study: 27071386

Group type: COMPARATOR
Intervention: EUS‐FNA (22G EchoTip Ultra needle)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: EUS‐FNB (22G EchoTip ProCore needle)
Number of subjects: 408
Study: 25722177

Group type: EXPERIMENTAL
Intervention: PMCT-10min test
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PMCT-2min test
Number of subjects: 49

Group type: COMPARATOR
Intervention: Younger participants
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Older participants
Number of subjects: 49
Study: 23295878

Group type: EXPERIMENTAL
Intervention: Artesunate + amodiaquine
Number of subjects: 210

Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 210
Study: 20938357

Group type: EXPERIMENTAL
Intervention: Plyometric training group (PG)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Loaded plyometric group (LPG, weighted vests 10-11% body mass)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no plyometric training)
Number of subjects: 27
Study: 18580553

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Continuation ECT
Number of subjects: 624

Group type: COMPARATOR
Intervention: Continuation pharmacotherapy
Number of subjects: 624
Study: 16213233

Group type: EXPERIMENTAL
Intervention: Virtual reality-enhanced exercise protocol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-VR group (control)
Number of subjects: 32
Study: 11791829

Group type: EXPERIMENTAL
Intervention: Hospital at Home
Number of subjects: 199

Group type: COMPARATOR
Intervention: Hospital
Number of subjects: 199
Study: 10527974

Group type: EXPERIMENTAL
Intervention: Normal fertile women
Number of subjects: 53

Group type: COMPARATOR
Intervention: Women with unexplained infertility
Number of subjects: 53
Study: 8742775

Group type: EXPERIMENTAL
Intervention: Psychological and pharmacological treatment (specifics not available)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment (e.g., Dual Diagnosis Relapse Prevention treatment with desipramine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment of anxiety, mood, and psychotic disorders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific psychosocial treatment techniques for subgroups of dually diagnosed patients
Number of subjects: 0
Study: 2032103

Group type: EXPERIMENTAL
Intervention: Consultant assessment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Research fellow assessment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Anal endosonography (initial criteria)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Anal endosonography (revised criteria)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Consultant assessment vs Anal endosonography
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Consultant assessment of secondary supralevator and infralevator tracks
Number of subjects: 38
Study: 6383116

Group type: EXPERIMENTAL
Intervention: Lignocaine 1% with adrenaline 1:100,000
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lignocaine 1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procaine 1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 0
Study: 31032904

Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit sent directly
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Invitation to order a HPV self-sampling kit using a new open source eHealth web application
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Invitation to call a coordinating midwife with questions and concerns
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Standard annual renewed invitation letter with prebooked appointment time (routine practice)
Number of subjects: 8000
Study: 30003459

Group type: EXPERIMENTAL
Intervention: Links to publicly accessible online prevention content via email
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no internet content received)
Number of subjects: 60
Study: 26554884

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 1,000 IU/day/orally (n = 80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (n = 80)
Number of subjects: 160
Study: 25458024

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo procedure (sham acupuncture)
Number of subjects: 36
Study: 22158728

Group type: COMPARATOR
Intervention: Exposure + tangible reward (sticker)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Exposure + social reward (praise)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: No-treatment control
Number of subjects: 173
Study: 20378684

Group type: EXPERIMENTAL
Intervention: vodka
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: white wine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: red wine
Number of subjects: 45

Group type: COMPARATOR
Intervention: water
Number of subjects: 45
Study: 21974759

Group type: EXPERIMENTAL
Intervention: valsartan/HCTZ 160/12.5 mg
Number of subjects: 384

Group type: COMPARATOR
Intervention: valsartan 160 mg
Number of subjects: 384

Group type: COMPARATOR
Intervention: HCTZ 12.5 mg
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: valsartan/HCTZ
Number of subjects: 384

Group type: COMPARATOR
Intervention: HCTZ
Number of subjects: 384

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 384
Study: 16081882

Group type: EXPERIMENTAL
Intervention: G773D variant in elastin
Number of subjects: 0
Study: 12659404

Group type: EXPERIMENTAL
Intervention: DRSP/EE (Yasmin)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9756050

Group type: EXPERIMENTAL
Intervention: Treatment compliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attendance at therapy sessions
Number of subjects: 0
Study: 8056129

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice a day)
Number of subjects: 10
Study: 3382038

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.67 mg/kg with atropine doses ranging from 0.0125 to 0.0215 mg/kg (group A, n = 37)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg/kg with atropine doses ranging from 0.02 to 0.04 mg/kg (group B, n = 35)
Number of subjects: 72
Study: 29304907

Group type: EXPERIMENTAL
Intervention: Natural frequencies
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conditional probabilities
Number of subjects: 14